Baricitinib

Kathryn Dzintars, Pharm.D., BCPS
Baricitinib is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or .

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

-- The first section of this topic is shown below --

INDICATIONS

FDA

The FDA issued an Emergency Use Authorization (EUA) permitting the use of baricitinib, in combination with remdesivir, for treatment of suspected or laboratory-confirmed COVID-19 disease in hospitalized adults and pediatric patients (> 2 years of age) requiring supplemental oxygen, invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO).

Patient Selection

  • Evaluate baseline eGFR, liver enzymes, and complete blood count to determine treatment suitability. Monitor patients with abnormal baseline values closely.
  • Baricitinib is not recommended for:
    • Patients with ESRD, or those receiving dialysis
    • Patients with known active tuberculosis
  • Limited information is available on the use of baricitinib in combination with systemic corticosteroids for the management of patients with COVID-19.

To request baricitinib under the EUA, inpatient pharmacies may order directly from an Authorized Distributor or Record. See www.baricitinibemergencyuse.com for additional information.

> Baricitinib is FDA approved in adult patients for the management of moderate to severe active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF)-antagonist therapies. No additional information related to this treatment indication will be included in the rest of the drug summary.

-- To view the remaining sections of this topic, please or --

INDICATIONS

FDA

The FDA issued an Emergency Use Authorization (EUA) permitting the use of baricitinib, in combination with remdesivir, for treatment of suspected or laboratory-confirmed COVID-19 disease in hospitalized adults and pediatric patients (> 2 years of age) requiring supplemental oxygen, invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO).

Patient Selection

  • Evaluate baseline eGFR, liver enzymes, and complete blood count to determine treatment suitability. Monitor patients with abnormal baseline values closely.
  • Baricitinib is not recommended for:
    • Patients with ESRD, or those receiving dialysis
    • Patients with known active tuberculosis
  • Limited information is available on the use of baricitinib in combination with systemic corticosteroids for the management of patients with COVID-19.

To request baricitinib under the EUA, inpatient pharmacies may order directly from an Authorized Distributor or Record. See www.baricitinibemergencyuse.com for additional information.

> Baricitinib is FDA approved in adult patients for the management of moderate to severe active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF)-antagonist therapies. No additional information related to this treatment indication will be included in the rest of the drug summary.

There's more to see -- the rest of this entry is available only to subscribers.

Last updated: December 7, 2020